Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis Extends Breakout As Three Key Drivers Lead To A Beat-And-Raise
09:11am, Tuesday, 25'th Apr 2023
Novartis stock jumped early Tuesday on a trio of drugs that helped drive its first-quarter earnings report to a beat-and-raise. The post Novartis Extends Breakout As Three Key Drivers Lead To A Beat-A
Novartis raises 2023 view, after posting higher profit and sales
01:44am, Tuesday, 25'th Apr 2023
Novartis AG on Tuesday posted slightly higher net profit and sales for the first quarter of the year, beating analysts' expectations, and raised its guidance for the full year.
Here's Why Novartis (NVS) is a Strong Value Stock
11:29am, Wednesday, 19'th Apr 2023
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are You Looking for a High-Growth Dividend Stock?
12:56pm, Monday, 17'th Apr 2023
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes?
2 Best Biotech Stocks to Buy for the Long Haul
05:10am, Monday, 17'th Apr 2023
Johnson & Johnson and Novartis both have robust product portfolios and pipelines. Each company pays a safe and market-topping dividend to shareholders.
The FDA Is Resuming Drug Lab Inspections in China. These Biotechs Could Benefit.
02:45pm, Friday, 14'th Apr 2023
China's pandemic-era travel restrictions paused approvals on some new drugs. The end of Zero Covid means the pipeline will reopen.
Novartis Shares Leap On Positive Clinical Trial Data
06:55am, Monday, 10'th Apr 2023
If you're looking to jump onboard a rocket, forget Jeff Bezos and Richard Branson. Shares of Swiss pharmaceutical giant Novartis AG (NYSE: NVS) catapulted 5.11% in the past week and 17.47% in the past
Novartis (NVS) Gets CHMP Positive Opinion for Entresto Approval
01:41pm, Monday, 03'rd Apr 2023
Novartis (NVS) receives a positive opinion from the CHMP for Entresto (sacubitril/valsartan) for a new indication in pediatric patients.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:59am, Wednesday, 29'th Mar 2023
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Novartis (NVS) Kisqali Positive for Early Breast Cancer
01:45pm, Monday, 27'th Mar 2023
Novartis (NVS) Kisqali meets primary endpoint of invasive disease-free survival in certain patients with early breast cancer at risk of recurrence.
Novartis Surges As It Goes After Eli Lilly's Second Biggest Moneymaker
10:17am, Monday, 27'th Mar 2023
Novartis stock surged Monday after the company's treatment reduced the risk of relapse in patients with early-stage breast cancer. The post Novartis Surges As It Goes After Eli Lilly's Second Biggest
First Citizens shares leap on SVB deal as Novartis stock boosted by breast-cancer drug trial
07:43am, Monday, 27'th Mar 2023
Here were some of the most active stocks in premarket trade, as U.S. stock index futures were boosted on improving news from the banking sector.
Novartis gets positive result from breast-cancer drug trial
02:48am, Monday, 27'th Mar 2023
Novartis AG said Monday that a trial evaluating breast-cancer drug Kisqali met its primary endpoint during an interim analysis.
My Top 10 Dividend Growth Stocks For March 2023
02:00pm, Thursday, 23'rd Mar 2023
In today's article, I will present 10 dividend growth companies that I currently consider to be particularly attractive. The 10 selected picks have shown an Average Dividend Growth Rate of 12.92% over
Novartis (NVS) Oncology Drug Gets FDA Nod for Label Expansion
02:31pm, Friday, 17'th Mar 2023
Novartis (NVS) obtains FDAs approval for the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) for pediatric brain cancer.
